Voluntary vitamin D claims: when are they allowed?

Under EU law, adding vitamin D to food is voluntary — but invoking a health claim is not. The two are separated by a specific quantitative threshold, a defined list of permitted statements, and a regulatory architecture that turns marketing language into a compliance exercise rather than a creative one.

The distinction matters because the assumption that "fortified" implies "claim-eligible" is one of the more persistent myths of the European functional-food market. It isn't true. A manufacturer can legally fortify a product and still find themselves unable to write a single health sentence on the pack. The mechanism is not industry-hostile — it's just biochemical reality dressed in legalese. What follows is the route through that legalese.

The Regulatory Framework for Voluntary Vitamin D Addition

The starting point is Regulation (EC) No 1925/2006, adopted in 2006, which harmonised the rules around voluntary addition of vitamins and minerals to foods across EU Member States. Before this framework, national approaches diverged widely: some Member States effectively restricted fortification beyond a narrow list of staple foods, others tolerated it loosely. The 2006 regulation established a single architecture while preserving room for national variation — meaning a product compliant in one Member State may face additional restrictions in another, but the foundational logic is uniform.

The companion regulation, (EC) No 1924/2006 on nutrition and health claims made on foods, sits alongside it. Together the two create a two-track system: one for the act of adding the nutrient, another for communicating its presence. The 2011 Regulation (EU) No 1169/2011 on food information to consumers then layered in mandatory labelling requirements — including the Nutrient Reference Values that the claims system ultimately leans on.

Fifteen percent of NRV: not a rounding error, not a guideline. The line between "food" and "claim-bearing food."

For voluntary fortification, the basic proposition is straightforward. A manufacturer may add vitamin D to a food provided the addition is safe, complies with applicable composition rules, and does not mislead the consumer about the nutritional quality of the product. There is no EU-wide maximum level for vitamin D in voluntarily fortified foods that applies uniformly across the general food supply — maximum levels remain, in part, a national competence, and the European Commission has been working toward harmonised limits for years without finalising them. EFSA's 2016 Scientific Opinion on Dietary Reference Values for vitamin D explicitly flagged the absence of harmonised maximum permitted levels as a regulatory gap. The practical consequence: a product compliant in Germany may need reformulation for France, and a formulation accepted in Sweden may not transfer cleanly to Italy. National variation is a permanent feature, not a transitional one.

Defining the "Significant Amount" Threshold

Here is where the marketing department runs into the biochemistry lab. To use a nutrition claim ("source of vitamin D") or any health claim for vitamin D, the product must contain what EU law calls a "significant amount" of the nutrient. That term is not a vibe. It is a number.

Under Regulations (EC) No 1924/2006 and (EU) No 1169/2011, the threshold is defined as:

• At least 15% of the Nutrient Reference Value (NRV) per 100 g or 100 mL for solid foods.
• At least 7.5% of NRV per 100 mL for beverages.

The NRV for vitamin D, set in Annex XIII of Regulation (EU) No 1169/2011, is 5 µg per day. The arithmetic follows. To carry a "source of vitamin D" claim, a solid food must contain at least 0.75 µg per 100 g; a beverage, at least 0.375 µg per 100 mL. These are not large doses. They are not clinically meaningful in isolation — they are regulatory floors, the minimum quantity that allows the label to legally say what the manufacturer wants it to say.

The 30% threshold for "rich in" or "high in" claims is a separate and stricter category — relevant for manufacturers who want bolder front-of-pack language. So why does the precise number matter? Because the threshold is binary. Fall below it, and the claim cannot be made — regardless of how the product is marketed, what the back of pack says, or what the website copy implies. The presence of added vitamin D alone is not enough. The quantity, per the defined reference quantity, must clear the bar. No assay method, no matter how rigorous, can rescue a product that falls 0.1 µg short.

EFSA-Authorised Health Claims and Required Wording

Even when a product clears the significant-amount threshold, the wording on the pack is not a free-text field. EFSA has authorised a closed list of permitted health claims for vitamin D under Article 13(1) of Regulation (EC) No 1924/2006. These are general function claims, evaluated for scientific substantiation before they reach the regulation.

The authorised statements include:

• "Vitamin D contributes to the maintenance of normal bones."
• "Vitamin D contributes to normal absorption/utilisation of calcium and phosphorus."

Each of these claims is supported by a defined physiological mechanism — not a marketing abstraction. The first refers to the established role of vitamin D in bone mineralisation through calcium homeostasis. The second refers to the intestinal transport mechanisms that require vitamin D as a cofactor for the active absorption of calcium and phosphate. These are textbook biochemistry. They are also the only general function claims EFSA has cleared for vitamin D under Article 13(1). There is no "vitamin D boosts immunity" on the list. There is no "vitamin D improves mood." The clinical biochemistry does not support those claims to the threshold EFSA applies, and the panel knows it. Substituting synonyms or extending the phrasing is not permitted: the regulation requires use of the authorised statement as approved.

For claims targeting children, EFSA has additionally authorised an Article 14 disease risk reduction claim: "Vitamin D is needed for the normal growth and development of bone in children." The phrasing is specific and conservative. It does not promise taller children, stronger skeletons beyond normal development, or any therapeutic outcome. It states the necessary condition: without adequate vitamin D, normal bone development in children is impaired.

Specific Conditions for the Disease Risk Reduction Claim

The single Article 14 disease risk reduction claim that EFSA has authorised for vitamin D is more clinically interesting — and considerably more demanding. It states that vitamin D helps reduce the risk of falling associated with postural instability and muscle weakness in adults aged 60 and older.

This claim carries conditions that go well beyond the basic significant-amount threshold. To use it on a food product, the manufacturer must:

• Target the claim at adults aged 60 and above.
• Ensure the product provides a daily intake of 20 µg of vitamin D — the quantity EFSA's NDA Panel identified as relevant for the effect.
• Use the claim only on products that deliver this amount in a reasonable daily portion.

The 20 µg figure is not the Adequate Intake. EFSA's Adequate Intake (AI), set in the 2016 Scientific Opinion on Dietary Reference Values for vitamin D, is 15 µg per day for healthy individuals over one year of age, including pregnant and lactating women. The 20 µg level specified in the falling-risk claim reflects the dose-response evidence the Panel reviewed for the postural stability and muscle function endpoint. The two figures answer different questions: AI answers "what is enough to avoid deficiency in the general population"; the claim-specific 20 µg answers "what dose has evidence for this specific functional outcome in older adults." The general function claim and the disease risk reduction claim are not interchangeable in dose, in target population, or in the substantiation file behind them.

Navigating Nutrient Reference Values in Product Formulation

For the biochemist-turned-formulator, the practical question is rarely "what claims can we make?" — it is "given our product matrix, what quantity of vitamin D do we need to add to clear each claim threshold per 100 g or 100 mL, and is that quantity compatible with the food's sensory and stability profile?" The formulation calculation proceeds from the back. Define the claim category first. Work backward through the percentage threshold. Then test against the matrix: lipophilic vitamin D in an aqueous beverage behaves differently from the same compound in a fat-based dairy matrix, and fortification strategies diverge accordingly.

A few formulation realities worth flagging:

• Stability: Vitamin D2 (ergocalciferol) and D3 (cholecalciferol) are sensitive to light, oxygen, and heat. A clear beverage in a transparent bottle is a poor host; an opaque, fat-containing matrix is a better one.
• Bioavailability: Vitamin D3 is generally regarded as more effective at raising serum 25(OH)D concentrations than D2 at equivalent doses — a metabolic question, not a regulatory one. The claims regime does not differentiate.
• Carrier systems: In powdered products, maltodextrin-stabilised vitamin D premixes are standard. In liquid dairy, fat-soluble preparations allow homogeneous distribution only when emulsification protocols are properly calibrated.
• Cross-contamination: For manufacturers running multiple product lines on shared equipment, cleaning validation must account for vitamin D carryover into products where it is not declared — particularly relevant for allergen-adjacent control programmes.

The mechanism is the same in every cell. The label is the only thing that varies.

The Biochemistry Beneath the Compliance

Pull back from the regulatory detail and the underlying picture is straightforward. Vitamin D is a fat-soluble seco-steroid. Its active form, 1,25-dihydroxyvitamin D (calcitriol), functions as a nuclear receptor ligand, modulating gene expression across a wide range of target genes. Its classical role — and the only one EFSA has cleared for general function claims — is calcium and phosphate homeostasis, with downstream effects on bone mineralisation. The muscle function claim, supported by vitamin D receptor expression in skeletal muscle and observational data on falling risk in older adults, sits at the edge of what evidence can support without overreaching.

The marketing layer frequently claims more. "Boosts immunity" is the most common. The clinical biochemistry is more cautious: vitamin D does modulate innate immune function, but EFSA has not authorised a claim to that effect because the evidence base has not met the threshold of cause-and-effect demonstration the regulation demands. This is not bureaucratic obstruction. It is the deliberate conservatism of a regulatory system that distinguishes between plausible mechanism and demonstrated effect. A claim that reads as plausible on the front of pack must clear that distinction before it reaches the label. Skip the threshold and the serum data will not rescue the claim — because the claim was never a clinical question in the first place. It is a regulatory one.

Practical Steps for a Manufacturer

For a manufacturer approaching voluntary vitamin D fortification with a claim in mind, the sequence is more linear than it first appears:

1. Determine the Member States of distribution. National additions to the EU framework may impose stricter limits and require national notification.

2. Choose the target claim. General function claims have lower formulation thresholds but narrower permitted wording. Disease risk reduction claims have higher dose requirements and specific population targeting.

3. Calculate the vitamin D quantity per 100 g or 100 mL needed to meet the 15% (solid) or 7.5% (beverage) NRV floor — and any higher target required by the specific claim category.

4. Verify stability, homogeneity, and sensory impact in the product matrix through validated analytical assays.

5. Draft label copy using only EFSA-authorised wording. Truncation, paraphrase, or extension of the claim text is not permitted.

6. Maintain documentation of the nutritional composition and the substantiation behind any claim-related efficacy assertions, in case of authority inquiry.

Step 6 has historically been the most expensive to skip. The claim substantiation file is the operational record that proves the manufacturer had evidence at the time of use — and "we assumed it was compliant" is not a defence that has aged well in enforcement actions.

The Verdict From the Bench

Voluntary vitamin D fortification is permitted across the EU. Health claims on vitamin D are permitted — but they are tightly bounded by quantitative thresholds and authorised wording. The framework is not a barrier to innovation. It is a filter that distinguishes between nutritional presence and claim-bearing nutritional presence, between general function and disease risk reduction, between "source of vitamin D" and "reduces the risk of falling in adults 60 and older."

The persistent industry assumption that adding the nutrient is the same as earning the claim is the real obstacle. It is not. The serum concentration required for clinical effect, the dose specified in the claim, and the percentage of NRV required on the label are three different numbers, each tied to a different regulatory question. Conflating them produces non-compliant labels, not better products. The biochemistry is settled. The regulation reflects it. The label must follow.